Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American academy of sleep medicine clinical practice guideline

Journal of Clinical Sleep Medicine

Volumn 13, Issue 2, 2017, Pages 307-349

  Sateia, Michael J ^a   Buysse, Daniel J ^b   Krystal, Andrew D ^c   Neubauer, David N ^d   Heald, Jonathan L ^e  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e American Academy of Sleep Medicine   (United States)

Author keywords

Guideline; Insomnia; Pharmacologic; Treatment

Indexed keywords

DIPHENHYDRAMINE; DOXEPIN; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; GABAPENTIN; MELATONIN; OXAZEPAM; PAROXETINE; QUAZEPAM; QUETIAPINE; RAMELTEON; SUVOREXANT; TEMAZEPAM; TIAGABINE; TRAZODONE; TRIAZOLAM; TRIMIPRAMINE; TRYPTOPHAN; VALERIAN; ZALEPLON; ZOLPIDEM; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CENTRAL DEPRESSANT AGENT; HYPNOTIC AGENT; HYPNOTIC SEDATIVE AGENT;

AROUSAL; ARTICLE; CHRONIC INSOMNIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG USE; HEALTH CARE COST; HUMAN; INSOMNIA; PATIENT CARE; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY INSOMNIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP QUALITY; SLEEP TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADULT; CHRONIC DISEASE; ORGANIZATION; SLEEP MEDICINE; UNITED STATES;

ACADEMIES AND INSTITUTES; ADULT; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHRONIC DISEASE; GABA MODULATORS; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP AIDS, PHARMACEUTICAL; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP MEDICINE SPECIALTY; UNITED STATES;

EID: 85015987598     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.6470     Document Type: Article

References (175)

1. 2005 Adult sleep habits and styles. National Sleep Foundation Web site. https://sleepfoundation. org/sites/default/files/2005-summary-of-findings. pdf. Published 2005. Accessed June 2016.
2. Kassam A, Patten SB. Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Popul Health Metr. 2006;4:15.
3. Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010. Pharmacoepidemiol Drug Saf. 2016;25(6):637-645.
4. Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep. 1997;20(9):715-723.
5. Chesson A, Jr., Hartse K, Anderson WM, et al. Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 2000;23(2):237-241.
6. Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 2000;23(2):243-308.
7. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
8. Chesson AL, Jr., Anderson WM, Littner M, et al. Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 1999;22(8):1128-1133.
9. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep. 2006;29(11):1415-1419.
10. Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep. 2006;29(11):1398-1414.
11. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281(11):991-999.
12. Meolie AL, Rosen C, Kristo D, et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med. 2005;1(2):173-187.
13. NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. 2005;22(2):1-30.
14. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577-1601.
15. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133.
16. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
17. Ellis JG, Perlis ML, Neale LF, Espie CA, Bastien CH. The natural history of insomnia: focus on prevalence and incidence of acute insomnia. J Psychiatr Res. 2012;46(10):1278-1285.
18. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6(2):97-111.
19. Ohayon MM. Observation of the natural evolution of insomnia in the american general population cohort. Sleep Med Clin. 2009;4(1):87-92.
20. DiBonaventura M, Richard L, Kumar M, Forsythe A, Flores NM, Moline M. The Association between Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, Healthcare Resource Use. PLoS One. 2015;10(10):e0137117.
21. Spira AP, Kaufmann CN, Kasper JD, et al. Association between insomnia symptoms and functional status in U. S. older adults. J Gerontol B Psychol Sci Soc Sci. 2014;69 Suppl 1:S35-S41.
22. Leigh JP. Employee and job attributes as predictors of absenteeism in a national sample of workers: the importance of health and dangerous working conditions. Soc Sci Med. 1991;33(2):127-137.
23. Hagg SA, Toren K, Lindberg E. Role of sleep disturbances in occupational accidents among women. Scand J Work Environ Health. 2015;41(4):368-376.
24. Laugsand LE, Strand LB, Vatten LJ, Janszky I, Bjorngaard JH. Insomnia symptoms and risk for unintentional fatal injuries-the HUNT Study. Sleep. 2014;37(11):1777-1786.
25. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1-3):10-19.
26. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39(6):411-418.
27. Fernandez-Mendoza J, Vgontzas AN, Liao D, et al. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension. 2012;60(4):929-935.
28. Bathgate CJ, Edinger JD, Wyatt JK, Krystal AD. Objective but not subjective short sleep duration associated with increased risk for hypertension in individuals with insomnia. Sleep. 2016;39(5):1037-1045.
29. Daley M, Morin CM, LeBlanc M, Gregoire JP, Savard J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, good sleepers. Sleep. 2009;32(1):55-64.
30. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30(3):263-273.
31. Sivertsen B, Lallukka T, Salo P. The economic burden of insomnia at the workplace. An opportunity and time for intervention? Sleep. 2011;34(9):1151-1152.
32. Leger D, Guilleminault C, Bader G, Levy E, Paillard M. Medical and socioprofessional impact of insomnia. Sleep. 2002;25(6):625-629.
33. Kleinman NL, Brook RA, Doan JF, Melkonian AK, Baran RW. Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study. J Clin Psychiatry. 2009;70(8):1098-1104.
34. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev. 2002;(2):CD003161.
35. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Metaanalysis. Ann Intern Med. 2015;163(3):191-204.
36. Wu JQ, Appleman ER, Salazar RD, Ong JC. Cognitive behavioral therapy for insomnia comorbid with psychiatric and medical conditions: a meta-analysis. JAMA Intern Med. 2015;175(9):1461-1472.
37. Zachariae R, Lyby MS, Ritterband LM, O'Toole MS. Efficacy of internetdelivered cognitive-behavioral therapy for insomnia-a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2016;30:1-10.
38. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999-2010. Sleep. 2014;37(2):343-349.
39. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry. 1991;52 Suppl:16-23.
40. Roehrs T, Roth T. 'Hypnotic' prescription patterns in a large managed-care population. Sleep Med. 2004;5(5):463-466.
41. 2005 Adult Sleep Habits and Styles. National Sleep Foundation Web site. https://sleepfoundation. org/sleep-polls-data/sleep-in-america-poll/2005-adultsleep-habits-and-styles. Published 2005. Accessed March 2016.
42. Cheung JM, Atternas K, Melchior M, Marshall NS, Fois RA, Saini B. Primary health care practitioner perspectives on the management of insomnia: a pilot study. Aust J Prim Health. 2014;20(1):103-112.
43. Pawaskar MD, Joish VN, Camacho FT, Rasu RS, Balkrishnan R. The influence of co-morbidities on prescribing pharmacotherapy for insomnia: evidence from US national outpatient data 1995-2004. J Med Econ. 2008;11(1):41-56.
44. Siriwardena AN, Apekey T, Tilling M, Dyas JV, Middleton H, Orner R. General practitioners' preferences for managing insomnia and opportunities for reducing hypnotic prescribing. J Eval Clin Pract. 2010;16(4):731-737.
45. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997;278(24):2170-2177.
46. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Metaanalysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233.
47. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004;19(5):305-322.
48. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.
49. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-1350.
50. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.
51. Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs. 2014;28(9):799-816.
52. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2016;165(2):103-112.
53. Morgenthaler TI, Deriy L, Heald JL, Thomas SM. The evolution of the AASM clinical practice guidelines: another step forward. J Clin Sleep Med. 2016;12(1):129-135.
54. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136-148.
55. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265-2274.
56. Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, doubleblind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010;33(2):225-234.
57. Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebocontrolled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med. 2008;4(3):229-234.
58. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin. 2006;22(9):1633-1642.
59. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28(6):720-727.
60. Uchimura N, Kamijo A, Kuwahara H, et al. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia. Sleep Med. 2012;13(10):1247-1253.
61. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979-1991.
62. Boyle J, Trick L, Johnsen S, Roach J, Rubens R. Next-day cognition, psychomotor function, driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol. 2008;23(5):385-397.
63. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebocontrolled study in adults with chronic insomnia. Sleep. 2003;26(7):793-799.
64. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, work limitations. Sleep. 2007;30(8):959-968.
65. Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1402-1410.
66. Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol. 2010;202(2):171. e1-e171. e111.
67. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry. 2000;15(8):704-712.
68. Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med. 2000;1(1):41-49.
69. Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects. Prim Care Companion J Clin Psychiatry. 1999;1(4):114-120.
70. Elie R, Ruther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry. 1999;60(8):536-544.
71. Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol. 2000;15(3):141-152.
72. Dorsey CM, Lee KA, Scharf MB. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2004;26(10):1578-1586.
73. Herrmann WM, Kubicki ST, Boden S, Eich FX, Attali P, Coquelin JP. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation. J Int Med Res. 1993;21(6):306-322.
74. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med. 2004;164(17):1888-1896.
75. Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry. 2004;65(8):1128-1137.
76. Randall S, Roehrs TA, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep. 2012;35(11):1551-1557.
77. Ware JC, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol. 1997;20(2):116-125.
78. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol. 1998;13(3)191-198.
79. Staner L, Ertle S, Boeijinga P, et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl). 2005;181(4):790-798.
80. Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry. 2008;16(1):44-57.
81. Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. 2006;7(5):397-406.
82. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55(5):192-199.
83. Allain H, Arbus L, Schück S, Group ZS. Efficacy and safety of zolpidem administered 'as needed' in primary insomnia: results of a double-blind, placebo-controlled study. Clin Drug Investig. 2001;21(6):391-400.
84. Cluydts R, Peeters K, de Bouyalsky I, Lavoisy J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a doubleblind, randomized pilot study. J Int Med Res. 1998;26(1):13-24.
85. Hajak G, Cluydts R, Declerck A, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol. 2002;17(1):9-17.
86. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-term efficacy and safety of zolpidem extended-release 12. 5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31(1):79-90.
87. Maroo N, Hazra A, Das T. Efficacy and safety of a polyherbal sedativehypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. Indian J Pharmacol. 2013;45(1):34-39.
88. Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep. 2008;31(9):1277-1284.
89. Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M. Novel sublingual lowdose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep. 2013;36(2):189-196.
90. Staner C, Joly F, Jacquot N, et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr Med Res Opin. 2010;26(6):1423-1431.
91. Tu JH, Chung WC, Yang CY, Tzeng DS. A comparison between acupuncture versus zolpidem in the treatment of primary insomnia. Asian J Psychiatr. 2012;5(3):231-235.
92. Voshaar RC, van Balkom AJ, Zitman FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur Neuropsychopharmacol. 2004;14(4):301-306.
93. Walsh JK. Zolpidem "as needed" for the treatment of primary insomnia: a double-blind, placebo-controlled study. Sleep Med Rev. 2002;6 Suppl 1:S7-S10; discussion S10-S11, S31-S33.
94. Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep. 2000;23(8):1087-1096.
95. Zammit GK, Corser B, Doghramji K, et al. Sleep and residual sedation after administration of zaleplon, zolpidem, placebo during experimental middleof-the-night awakening. J Clin Sleep Med. 2006;2(4):417-423.
96. Roehrs T, Bonahoom A, Pedrosi B, Rosenthal L, Roth T. Treatment regimen and hypnotic self-administration. Psychopharmacology (Berl). 2001;155(1):11-17.
97. Elie R, Frenay M, Le Morvan P, Bourgouin J. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol. 1990;5 Suppl 2:39-46.
98. Reeves RL. Comparison of triazolam, flurazepam, placebo as hypnotics in geriatric patients with insomnia. J Clin Pharmacol. 1977;17(5-6):319-323.
99. Autret E, Maillard F, Autret A. Comparison of the clinical hypnotic effects of zopiclone and triazolam. Eur J Clin Pharmacol. 1987;31(5):621-623.
100. Bowen AJ. Comparative efficacy of triazolam, flurazepam and placebo in outpatients insomniacs. J Int Med Res. 1978;6(4):337-342.
101. Fabre LF, Jr., Gross L, Pasigajen V, Metzler C. Multiclinic double-blind comparison of triazolam and flurazepam for seven nights in outpatients with insomnia. J Clin Pharmacol. 1977;17(7):402-409.
102. Fleming JA, McClure DJ, Mayes C, Phillips R, Bourgouin J. A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol. 1990;5 Suppl 2:29-37.
103. Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med. 1987;317(12):722-728.
104. Hajak G, Clarenbach P, Fischer W, Haase W, Ruther E. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol. 1994;9(4):251-261.
105. Leibowitz M, Sunshine A. Long-term hypnotic efficacy and safety of triazolam and flurazepam. J Clin Pharmacol. 1978;18(5-6):302-309.
106. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia-a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry. 1994;27(4):166-175.
107. Rickels K, Gingrich RL, Jr., Morris RJ, et al. Triazolam in insomniac family practice patients. Clin Pharmacol Ther. 1975;18(3):315-324.
108. Scharf MB. Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, placebo. J Clin Psychiatry. 1993;54(1):33-38.
109. Sunshine A. Comparison of the hypnotic activity of triazolam, flurazepam hydrochloride, placebo. Clin Pharmacol Ther. 1975;17(5):573-577.
110. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2008;28(2):182-188.
111. Hindmarch I. Effects of hypnotic and sleep-inducing drugs on objective assessments of human psychomotor performance and subjective appraisals of sleep and early morning behaviour. Br J Clin Pharmacol. 1979;8(1):43S-46S.
112. Wu R, Bao J, Zhang C, Deng J, Long C. Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia. Psychother Psychosom. 2006;75(4):220-228.
113. Cuanang JR, Limos L. Treatment of insomnia with temazepam: double-blind, placebo-controlled evaluation. Clin Ther. 1982;4(5):402-412.
114. Fillingim JM. Double-blind evaluation of the efficacy and safety of temazepam in outpatients with insomnia. Br J Clin Pharmacol. 1979;8(1):73S-77S.
115. Heffron WA, Roth P. Double-blind evaluation of the safety and hypnotic efficacy of temazepam in insomniac outpatients. Br J Clin Pharmacol. 1979;8(1):69S-72S.
116. Tuk B, Oberye JJ, Pieters MS, et al. Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep. Clin Pharmacol Ther. 1997;62(4):444-452.
117. Wilson SJ, Rich AS, Rich NC, Potokar J, Nutt DJ. Evaluation of actigraphy and automated telephoned questionnaires to assess hypnotic effects in insomnia. Int Clin Psychopharmacol. 2004;19(2):77-84.
118. Kohsaka M, Kanemura T, Taniguchi M, et al. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia. Expert Rev Neurother. 2011;11(10):1389-1397.
119. Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009;32(3):351-360.
120. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23(5):1005-1014.
121. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3(5):495-504.
122. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7(1):17-24.
123. Mini L, Wang-Weigand S, Zhang J. Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect. Clin Ther. 2008;30(7):1316-1323.
124. Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother. 2007;5(3):177-184.
125. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7(4):312-318.
126. Wang-Weigand S, Watissee M, Roth T. Use of a post-sleep questionnaireinteractive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia. Sleep Med. 2011;12(9):920-923.
127. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep. 2010;33(11):1553-1561.
128. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34(10):1433-1442.
129. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555-1561.
130. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2008;69(10):1557-1564.
131. Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med. 2012;13(2):133-138.
132. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001;62(6):453-463.
133. Roth T, Wright KP, Jr., Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep. 2006;29(3):335-341.
134. Walsh JK, Perlis M, Rosenthal M, Krystal A, Jiang J, Roth T. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med. 2006;2(1):35-41.
135. Walsh JK, Zammit G, Schweitzer PK, Ondrasik J, Roth T. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med. 2006;7(2):155-161.
136. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005;28(11):1465-1471.
137. Rickels K, Morris RJ, Newman H, Rosenfeld H, Schiller H, Weinstock R. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol. 1983;23(5-6):234-242.
138. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16(4):372-380.
139. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24(5):239-249.
140. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23(10):2597-2605.
141. Baskett JJ, Broad JB, Wood PC, et al. Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing. 2003;32(2):164-170.
142. Garzon C, Guerrero JM, Aramburu O, Guzman T. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging Clin Exp Res. 2009;21(1):38-42.
143. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18(7):598-603.
144. Rondanelli M, Opizzi A, Monteferrario F, Antoniello N, Manni R, Klersy C. The effect of melatonin, magnesium, zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J Am Geriatr Soc. 2011;59(1):82-90.
145. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short-and long-term response. Curr Med Res Opin. 2011;27(1):87-98.
146. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:51.
147. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86(10):4727-4730.
148. Hudson C, Hudson SP, Hecht T, MacKenzie J. Protein source tryptophan versus pharmaceutical grade tryptophan as an efficacious treatment for chronic insomnia. Nutr Neurosci. 2005;8(2):121-127.
149. Hartmann E, Lindsley JG, Spinweber C. Chronic insomnia: effects of tryptophan, flurazepam, secobarbital, placebo. Psychopharmacology (Berl). 1983;80(2):138-142.
150. Spinweber CL. L-tryptophan administered to chronic sleep-onset insomniacs: late-appearing reduction of sleep latency. Psychopharmacology (Berl). 1986;90(2):151-155.
151. Oxman AD, Flottorp S, Havelsrud K, et al. A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia. PLoS One. 2007;2(10):e1040.
152. Cohn JB, Wilcox CS, Bremner J, Ettinger M. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. J Clin Pharmacol. 1991;31(8):747-750.
153. Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM. Comparative efficacy of estazolam, flurazepam, placebo in outpatients with insomnia. J Clin Psychiatry. 1986;47(7):362-365.
154. Scharf MB, Roth PB, Dominguez RA, Ware JC. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol. 1990;30(5):461-467.
155. Aden GC, Thatcher C. Quazepam in the short-term treatment of insomnia in outpatients. J Clin Psychiatry. 1983;44(12):454-456.
156. Hernandez Lara R, Del Rosal PL, Ponce MC. Short-term study of quazepam 15 milligrams in the treatment of insomnia. J Int Med Res. 1983;11(3):162-166.
157. Martinez HT, Serna CT. Short-term treatment with quazepam of insomnia in geriatric patients. Clin Ther. 1982;5(2):174-178.
158. Mendels J, Stern S. Evaluation of the short-term treatment of insomnia in outpatients with 15 milligrams of quazepam. J Int Med Res. 1983;11(3):155-161.
159. O'Hair DE, Winsauer HJ. Evaluation of short-term treatment with 30 mg of quazepam in insomniac outpatients. Clin Ther. 1981;4(4):291-301.
160. Roth TG, Roehrs TA, Koshorek GL, Greenblatt DJ, Rosenthal LD. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol. 1997;17(5):401-406.
161. Elie R, Caille G, Levasseur FA, Gareau J. Comparative hypnotic activity of single doses of loprazolam, flurazepam, placebo. J Clin Pharmacol. 1983;23(1):32-36.
162. Elie R, Lavoie G, Bourgouin J, Le Morvan P. Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol. 1990;5(4):279-286.
163. Kripke DF, Hauri P, Ancoli-Israel S, Roth T. Sleep evaluation in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol. 1990;10(4 Suppl):32S-43S.
164. Mamelak M, Buck L, Csima A, Price V, Smiley A. Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction. Sleep. 1987;10 Suppl 1:79-87.
165. Mamelak M, Csima A, Buck L, Price V. A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol. 1989;9(4):260-267.
166. Melo de Paula AJ. Comparative study of lormetazepam and flurazepam in the treatment of insomnia. Clin Ther. 1984;6(4):500-508.
167. Salkind MR, Silverstone T. A clinical and psychometric evaluation of flurazepam. Br J Clin Pharmacol. 1975;2(3):223-226.
168. Gotestam KG, Oppoyen F, Berntzen D. Treatment of insomnia with two benzodiazepines: a double-blind crossover study. Eur J Clin Pharmacol. 1991;41(2):137-140.
169. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai. 2010;93(6):729-734.
170. Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 2010;33(2):84-90.
171. Nowell PD, Reynolds CF, 3rd, Buysse DJ, Dew MA, Kupfer DJ. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry. 1999;60(2):89-95.
172. Reynolds CF, 3rd, Buysse DJ, Miller MD, Pollock BG, Hall M, Mazumdar S. Paroxetine treatment of primary insomnia in older adults. Am J Geriatr Psychiatry. 2006;14(9):803-807.
173. Hohagen F, Montero RF, Weiss E, et al. Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci. 1994;244(2):65-72.
174. Riemann D, Voderholzer U, Cohrs S, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry. 2002;35(5):165-174.
175. Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159(1):5-11.